Entrada Therapeutics (TRDA) – Research Analysts’ Recent Ratings Changes

Entrada Therapeutics (NASDAQ: TRDA) has recently received a number of price target changes and ratings updates:

• 4/6/2026 – Entrada Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $21.00 to $23.00. They now have an “outperform” rating on the stock.
• 4/1/2026 – Entrada Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 3/28/2026 – Entrada Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/27/2026 – Entrada Therapeutics had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 2/28/2026 – Entrada Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/18/2026 – Entrada Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 2/11/2026 – Entrada Therapeutics was upgraded by Guggenheim to “strong-buy”.
• 2/10/2026 – Entrada Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $20.00 price target on the stock.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, COO Nathan J. Dowden sold 11,894 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $13.05, for a total value of $155,216.70. Following the completion of the sale, the chief operating officer owned 198,588 shares of the company’s stock, valued at $2,591,573.40. This trade represents a 5.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kory James Wentworth sold 2,500 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total transaction of $32,375.00. Following the completion of the sale, the chief financial officer directly owned 119,010 shares of the company’s stock, valued at $1,541,179.50. This trade represents a 2.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 41,975 shares of company stock valued at $540,444 in the last ninety days. 8.11% of the stock is owned by corporate insiders.

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.